RT Journal Article
SR Electronic
T1 High-frequency screening combined with diagnostic testing for control of SARS-CoV-2 in high-density settings: an economic evaluation of resources allocation for public health benefit
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.04.21252949
DO 10.1101/2021.03.04.21252949
A1 Rogers, Will
A1 Ruiz-Aravena, Manuel
A1 Hansen, Dale
A1 Madden, Wyatt
A1 Kessler, Maureen
A1 Fields, Matthew W.
A1 Ferrari, Matthew J.
A1 Chang, Connie B.
A1 Morrow, Jayne
A1 Hoegh, Andrew
A1 Plowright, Raina K.
YR 2021
UL http://medrxiv.org/content/early/2021/03/09/2021.03.04.21252949.abstract
AB SARS-CoV-2 spreads quickly in dense populations, with serious implications for universities, workplaces, and other settings where exposure reduction practices are difficult to implement. Rapid screening has been proposed as a tool to slow the spread of the virus; however, many commonly used diagnostic tests (e.g., RT-qPCR) are expensive, difficult to deploy (e.g., require a nasopharyngeal specimen), and have extended turn-around times. We evaluated testing regimes that combined diagnostic testing using qPCR with high-frequency screening using a novel reverse-transcription loop-mediated isothermal amplification (RT-LAMP, herein LAMP) assay. We used a compartmental susceptible-exposed-infectious-recovered (SEIR) model to simulate screening of a university population. We also developed a Shiny application to allow administrators and public health professionals to develop optimal testing strategies given site-specific assumptions about testing investment, target population, and cost. The frequency of screening, especially when pooling samples, was more important for minimizing epidemic size than test sensitivity, behavioral compliance, contact tracing capacity, and time between testing and results. Our results suggest that when testing budgets are limited, it is safer and more cost-effective to allocate the majority of funds to screening. Rapid, cost-effective, and scalable screening tests, like LAMP, should be viewed as critical components of SARS-CoV-2 testing in high-density populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by Coronavirus Aid, Relief and Economic Security Act, or CARES Act, grant titled "Expanding Screening Capacity to Enhance Montana's COVID-19 Response Capabilities". RKP was funded by the DARPA PREEMPT program Cooperative Agreement # D18AC00031, the U.S. National Science Foundation (DEB-1716698), and the USDA National Institute of Food and Agriculture (Hatch project 1015891). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. The funders did not play any role in the collection, analysis, interpretation, writing of final reports or decision to submit this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There were no human subjects in this modeling study, so no IRB/oversight body was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere are no original data in this modeling study. All code to generate data used in the study are available at https://github.com/wilrogers/COVID-Modeling. https://github.com/wilrogers/COVID-Modeling